-
AstraZeneca CEO: Closing In On A Cancer Cure
Friday, November 22, 2019 - 4:39pm | 504Read More...Biotech is making great strides in oncology. “I think we are within striking distance of curing some cancers or actually improving survival rates to 90% or above,” AstraZeneca plc (NYSE: AZN) CEO Pascal Soriot told CNBC of the field. Progress is partly owed to diagnostics. Tech...
-
AstraZeneca Falls More Than 5% Following Q4 Print
Thursday, February 4, 2016 - 9:03am | 268Read More...Shares of AstraZeneca plc (ADR) (NYSE: AZN) were trading lower by more than 5 percent early Thursday morning after the company reported its fourth quarter results. AstraZeneca earned $0.94 per share in the fourth quarter on revenue of $6.39 billion. Wall Street analysts were expecting the...
-
Report: AstraZeneca Eyes Acquisition Of Relypsa For $46 Per Share
Thursday, December 24, 2015 - 8:53am | 122Read More...Shares of Relypsa Inc (NASDAQ: RLYP) were trading higher by more than 2 percent at $28.60 early Thursday morning after the Daily Mail reported the company may be a potential acquisition target. The Daily Mail reported that "rumors from across the Pond" suggest that AstraZeneca plc (...
-
AstraZeneca CEO: We Will Achieve Our Targets Through Our Drug Pipeline
Friday, November 28, 2014 - 11:53am | 314Read More...While talks with Pfizer are going nowhere at the moment, the best course of action for AstraZeneca plc (ADR) (NYSE: AZN) seems to be focusing on its own drug pipeline and that’s exactly what the company seems to be doing. Pascal Soriot, CEO of AstraZeneca, was recently on CNBC to discuss...
-
Big Pharma's Next Blockbuster is Fish Oil?
Friday, June 28, 2013 - 11:42am | 529Read More...You might take it now. It’s marketed as being beneficial to patients with everything from depression issues to those who want a full head of hair, but drug companies like AstraZeneca (NYSE: AZN), Amarin (NASDAQ: AMRN) and GlaxoSmithKline (NYSE: GSK) are betting on it for another reason. Heart...
